Shortened Radioimmunoassay for Human Growth Hormone

Abstract We report a radioimmunoassay procedure for human growth hormone in serum, in which the assay mixture is incubated at 37 °C for a total of 5 h rather than at 4 °C for 48 h. There was no significant difference in results by the two methods, according to the Sign Test and the signed-rank statistical test of Wilcoxin. A comparison of results at the two temperatures demonstrated a Spearmann coefficient of rank correlation value of 0.94. With this facilitation, a laboratory can provide results on the same day that the sample arrives.

Download Full-text

In Vivo Bioassay of Recombinant Human Growth Hormone Synthesized inB. moriPupae

Journal of Biomedicine and Biotechnology ◽

10.1155/2010/306462 ◽

2010 ◽

Vol 2010 ◽

pp. 1-6 ◽

Cited By ~ 2

Author(s):

Hanglian Lan ◽

Zuoming Nie ◽

Yue Liu ◽

Zhengbing Lv ◽

Yingshuo Liu ◽

...

Keyword(s):

Growth Hormone ◽

Human Growth Hormone ◽

Recombinant Human Growth Hormone ◽

Expression System ◽

Human Growth ◽

The Body ◽

Control Group ◽

Prokaryotic Expression System ◽

Significant Difference ◽

Baculovirus System

The human growth hormone (hGH) has been expressed in prokaryotic expression system with low bioactivity previously. Then the effectiveB. moribaculovirus system was employed to express hGH identical to mature hGH successfully in larvae, but the expression level was still limited. In this work, the hGH was expressed inB. moripupae by baculovirus system. Quantification of recombinant hGH protein (BmrhGH) showed that the expression of BmrhGH reached the level of approximately 890 μg/mL pupae supernatant solution, which was five times more than the level using larvae. Furthermore, Animals were gavaged with BmrhGH at the dose of 4.5 mg/rat.day, and the body weight gain (BWG) of treated group had a significant difference (P<.01) compared with the control group. The other two parameters of liver weight and epiphyseal width were also found to be different between the two groups (P<.05). The results suggested that BmrhGH might be used as a protein drug by oral administration.

Download Full-text

Subcutaneous Absorption Kinetics of Two Highly Concentrated Preparations of Recombinant Human Growth Hormone

Annals of Pharmacotherapy ◽

10.1177/106002809302700402 ◽

1993 ◽

Vol 27 (4) ◽

pp. 411-415 ◽

Cited By ~ 7

Author(s):

Torben Laursen ◽

Jens O.L. Jørgensen ◽

Søren Susgaard ◽

Jens Møller ◽

Jens S. Christiansen

Keyword(s):

Growth Hormone ◽

Human Growth Hormone ◽

Geometric Mean ◽

Human Growth ◽

Metabolic Effects ◽

Interindividual Variation ◽

Absorption Kinetics ◽

Short Term ◽

Significant Difference ◽

Relative Absorption

OBJECTIVE: The relative bioavailability of two highly concentrated (12 IU/mL) formulations of biosynthetic human growth hormone (GH) administered subcutaneously was compared. DESIGN: A randomized, crossover study. Conventional GH therapy was withdrawn 72 hours before each study period. There was a washout period of at least four weeks between the study periods. SETTING: Participants were recruited from an outpatient clinic and were hospitalized during the two study periods. PATIENTS: Fourteen GH-deficient patients (mean age 25.2 y, range 14–54). One patient was excluded from data analysis because of signs of endogenous GH secretion. INTERVENTIONS: At the start of each study period, GH 3 IU/m2 was injected subcutaneously. The two formulations, PenFill and PenSet, differ in the buffers used and in the relative content of mannitol and glycine. Serum profiles of GH were monitored frequently for 24 hours. Samples were taken every 30 minutes for 6 hours and then hourly. MAIN OUTCOME MEASURES: Bioavailability (F) and absorption dynamics of human GH were measured. The relative absorption fractions estimated from the areas under the individual serum concentration curves from 0 to 24 hours, and the observed time (Tmax) to reach the maximum concentration (Cmax) were determined. Short-term metabolic effects of GH on insulin-like growth factor (IGF-I), glucose, and insulin were determined. RESULTS: The geometric mean (SD) of F was 0.910 (1.236). The 90 percent confidence interval was 0.819–1.010. Mean (± SD) of Cmax was 12.65 ± 5.89 and 12.58 ± 4.40 ng/mL for PenFill and PenSet, respectively. Corresponding values for Tmax were 5.49 ± 1.55 and 5.89 ± 1.79 hours for PenFill and PenSet, respectively. There was a considerable interindividual variation, but the relative absorption fraction did not significantly differ from 1 (p=0.13). Neither Cmax (p=0.74) nor Tmax (p=0.58) of the two formulations was significantly different. Injection of the two formulations induced similar increments in serum IFG-I (p=0.48). Serum insulin and blood glucose concentrations were not significantly different. CONCLUSIONS: There is no significant difference between the absorption kinetics and short-term metabolic effects of these two highly concentrated formulations of biosynthetic GH. The two formulations are bioequivalent.

Download Full-text

Insulin Tolerance Test: human growth hormone response and insulin resistance in primary unipolar depressed, bipolar depressed and control subjects

Psychological Medicine ◽

10.1017/s0033291700043270 ◽

1982 ◽

Vol 12 (1) ◽

pp. 45-55 ◽

Cited By ~ 42

Author(s):

Stephen H. Koslow ◽

Peter E. Stokes ◽

Joseph Mendels ◽

Alan Ramsey ◽

Regina Casper

Keyword(s):

Growth Hormone ◽

Human Growth Hormone ◽

Human Growth ◽

Tolerance Test ◽

Insulin Tolerance Test ◽

Control Subjects ◽

Insulin Tolerance ◽

Significant Difference ◽

Pre Treatment ◽

And Control

SynopsisPreliminary data from the National Institute of Mental Health – Clinical Research Branch Collaborative Program on the Psychobiology of Depression dealing with the human growth hormone (hGH) response to the Insulin Tolerance Test (ITT) during the pre-treatment (drug-free) period of the study are presented in this paper. Data are reported for 54 unipolar depressed, 21 bipolar depressed, and 40 normal control subjects, who represent approximately 50% of the final subject sample to be studied. In this population the unipolar depressed subjects showed a significantly greater resistance to insulin-induced hypoglycaemia than bipolar and control subjects. After applying the inclusion/exclusion criteria necessary to interpret hGH responses accurately, the data from only 54 subjects were acceptable. Mean peak hGH concentrations were not significantly different among the three groups. There was, however, a significant difference in the distributions of the hGH peak response, with the bipolar depressed population demonstrating greater variability in response than unipolar and control populations. These findings are discussed as they relate to previous reports and theoretical considerations.

Download Full-text